DNA Damage Is a Potential Marker for TP53 Mutation in Colorectal Carcinogenesis

被引:0
|
作者
Scalise J.R. [1 ]
Poças R.C.G. [1 ]
Caneloi T.P. [2 ]
Lopes C.O. [2 ]
Kanno D.T. [2 ]
Marques M.G. [2 ]
Valdivia J.C.M. [2 ]
Maximo F.R. [2 ]
Pereira J.A. [3 ]
Ribeiro M.L. [1 ]
Priolli D.G. [1 ,4 ]
机构
[1] Postgraduate Programme Strictu Senso in Health Science, Sao Francisco University Medical School, Sao Paulo
[2] Scientific Initiation Student, Scientific Initiation Programme, Sao Francisco University Medical School, Sao Paulo
[3] Department of Pathology, Sao Francisco University Medical School, Sao Paulo
[4] Rua São Vicente 614. Jardim Paulista, Atibaia, CEP: 12947-390, SP
基金
巴西圣保罗研究基金会;
关键词
Adenocarcinoma; Adenoma; DNA damage; Immunohistochemistry; Tumor suppressor protein p53;
D O I
10.1007/s12029-016-9846-0
中图分类号
学科分类号
摘要
Purpose: The ability to measure oxidative DNA damage in a tissue allows establishment of the relationship between DNA damage and mutations in normal and neoplastic cells. It is well known that TP53 is a key inhibitor of tumor development and preserves the genome integrity in each cell. The aim of the present study was to investigate the relationship between DNA damage and TP53 mutation in colorectal adenoma and adenocarcinoma, and the value of DNA damage as potential marker of TP53 mutation in non-tumor tissues adjacent to colon malignant lesions. Methods: Tissue samples were obtained by colonoscopy from patients with adenoma and/or adenocarcinoma and from healthy volunteers. Diagnosis was defined by histopathology. Immunohistochemistry with computer-assisted image analysis was performed to quantify TP53 mutation. Oxidative DNA damage was determined by comet assay. Statistical analyses were performed with 5 % of significance level. Results: The TP53 level was higher in non-tumor tissues from tumor patients than in normal tissues from healthy volunteers (p = 0.01). Likewise, higher TP53 levels were observed in tumor tissues compared with the non-tumor tissues (p = 0.00). Oxidative DNA damage levels were higher in tumor tissues than in non-tumor tissues (p = 0.00). The amount of TP53 (p = 0.00) and oxidative DNA damage (p = 0.00) in normal and tumor tissue was related. The relationship between oxidative DNA damage and TP53 mutation was demonstrated in all samples (p = 0.00). Conclusion: Oxidative DNA damage is an intervening variable for TP53 mutation in colorectal adenoma-carcinoma. Our data suggests that oxidative DNA damage is a potential marker of TP53 mutation in colorectal carcinogenesis. © 2016, Springer Science+Business Media New York.
引用
收藏
页码:409 / 416
页数:7
相关论文
共 50 条
  • [41] Functional categories of TP53 mutation in colorectal cancer:: results of an International Collaborative Study
    Iacopetta, B
    Russo, A
    Bazan, V
    Dardanoni, G
    Gebbia, N
    Soussi, T
    Kerr, D
    Elsaleh, H
    Soong, R
    Kandioler, D
    Janschek, E
    Kappel, S
    Lung, M
    Leung, CSS
    Ko, JM
    Yuen, S
    Ho, J
    Leung, SY
    Crapez, E
    Duffour, J
    Ychou, M
    Leahy, DT
    O'Donoghue, DP
    Agnese, V
    Cascio, S
    Di Fede, G
    Chieco-Bianchi, L
    Bertorelle, R
    Belluco, C
    Giaretti, W
    Castagnola, P
    Ricevuto, E
    Ficorella, C
    Bosari, S
    Arizzi, CD
    Miyaki, M
    Onda, M
    Kampman, E
    Diergaarde, B
    Royds, J
    Lothe, RA
    Diep, CB
    Meling, GI
    Ostrowski, J
    Trzeciak, L
    Guzinska-Ustymowicz, K
    Zalewski, B
    Capellá, GM
    Moreno, V
    Peinado, MA
    ANNALS OF ONCOLOGY, 2006, 17 (05) : 842 - 847
  • [42] Effect of TP53 mutation on antitumor immunity and responsiveness to immunotherapy in colorectal cancer.
    Lu, Zhihao
    Shen, Lin
    Zhang, Henghui
    Jiao, Xi
    Wang, Yujiao
    Chen, Huan
    Han, Wenbo
    Liu, Chang
    Gong, Jifang
    Li, Jian
    Zhang, Xiaotian
    Wang, Xicheng
    Peng, Zhi
    Qi, Changsong
    Wang, Zhenghang
    Li, Yanyan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] APC and TP53 as potential biomarkers for EGFR sensitivity in colorectal cancer.
    Thota, Ramya
    Yang, Mingli
    Davis, Thomas
    Schell, Michael J.
    Pledger, Warren Jack
    Yeatman, Timothy Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Is there an association between the TP53 codon 72 polymorphism and sperm DNA damage?
    Mattila, M.
    Petersen, C. G.
    Mauri, A. L.
    Vagnini, L. D.
    Renzi, A.
    Petersen, B.
    Zamara, C.
    Dieamant, F.
    Oliveira, J. B. A.
    Baruffi, R. L. R.
    Franco, J. G., Jr.
    HUMAN REPRODUCTION, 2019, 34 : 147 - 147
  • [45] MUT-TP53: A versatile matrix for TP53 mutation verification and publication
    Soussi, Thierry
    Rubio-Nevado, Jean Michel
    Ishioka, Chikashi
    HUMAN MUTATION, 2006, 27 (11) : 1151 - 1154
  • [46] Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations
    Soussi, T
    Kato, S
    Levy, PP
    Ishioka, C
    HUMAN MUTATION, 2005, 25 (01) : 6 - 17
  • [47] TP53 Promoter Methylation in Primary Glioblastoma: Relationship with TP53 mRNA and Protein Expression and Mutation Status
    Jesionek-Kupnicka, Dorota
    Szybka, Malgorzata
    Malachowska, Beata
    Fendler, Wojciech
    Potemski, Piotr
    Piaskowski, Sylwester
    Jaskolski, Dariusz
    Papierz, Wielislaw
    Skowronski, Wieslaw
    Och, Waldemar
    Kordek, Radzislaw
    Zawlik, Izabela
    DNA AND CELL BIOLOGY, 2014, 33 (04) : 217 - 226
  • [48] The Rb family connects with the Tp53 family in skin carcinogenesis
    Fernanda Lara, Maria
    Paramio, Jesus M.
    MOLECULAR CARCINOGENESIS, 2007, 46 (08) : 618 - 623
  • [49] Haploinsufficiency Interactions of RALBP1 and TP53 in Carcinogenesis
    Awasthi, Sanjay
    CANCERS, 2021, 13 (02)
  • [50] TP53 TUMOR-SUPPRESSOR GENE AND SKIN CARCINOGENESIS
    BASSETSEGUIN, N
    MOLES, JP
    MILS, V
    DEREURE, O
    GUILHOU, JJ
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 103 (05) : S102 - S106